CI Stock Analysis: The Cigna | NYSE
Healthcare Plans | NYSE, USA | Market Cap: 78.260m USD | 12M Return: 10.8% | US1255231003 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 491M
EPS Trend: 97.8%
Qual. Beats: 1
Rev. Trend: 96.2%
Qual. Beats: 15
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.9 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
The Cigna Group (NYSE: CI) is a major U.S. health services company headquartered in Bloomfield, Connecticut, operating two core segments: Evernorth Health Services, which covers pharmacy benefit management, specialty pharmacy distribution, and care services, and Cigna Healthcare, which delivers employer-sponsored medical plans, individual and family coverage, behavioral health, dental, and international health benefits. Its products are distributed through brokers, consultants, direct sales, and public and private exchanges. Originally founded in 1792 (one of the oldest U.S. corporations still operating) and formerly known as Cigna Corporation, the company adopted its current name in February 2023. As a large-cap constituent of the GICS Health Care sector, Cigna competes in the consolidated managed-care and pharmacy benefit management (PBM) industry, where insurers increasingly integrate drug-benefits administration with medical coverage to manage total health spending.
- Evernorth PBM margins pressured by drug pricing reform
- Medicare Advantage divestiture refocuses capital allocation strategy
- Specialty pharmacy demand grows alongside GLP-1 cost pressure
| Net Income: 5.99b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 0.53 > 1.0 |
| NWC/Revenue: -3.07% < 20% (prev -3.62%; Δ 0.55% < -1%) |
| CFO/TA 0.06 > 3% & CFO 9.43b > Net Income 5.99b |
| Net Debt (23.9b) to EBITDA (12.5b): 1.91 < 3 |
| Current Ratio: 0.84 > 1.5 & < 3 |
| Outstanding Shares: last quarter (263.8m) vs 12m ago -1.63% < -2% |
| Gross Margin: 10.26% > 18% (prev 10.03%; Δ 0.23% > 0.5%) |
| Asset Turnover: 181.5% > 50% (prev 169.8%; Δ 11.68% > 0%) |
| Interest Coverage Ratio: 6.98 > 6 (EBIT TTM 9.64b / Interest Expense TTM 1.38b) |
| A: -0.06 (Total Current Assets 47.2b - Total Current Liabilities 56.0b) / Total Assets 158b |
| B: 0.33 (Retained Earnings 51.4b / Total Assets 158b) |
| C: 0.06 (EBIT TTM 9.64b / Avg Total Assets 158b) |
| D: 0.38 (Book Value of Equity 43.4b / Total Liabilities 114b) |
| Altman-Z'' = 1.51 = BB |
| DSRI: 0.93 (Receivables 31.5b/31.7b, Revenue 286b/268b) |
| GMI: 0.98 (GM 10.03% / 10.26%) |
| AQI: 0.99 (AQ_t 0.68 / AQ_t-1 0.68) |
| SGI: 1.07 (Revenue 286b / 268b) |
| TATA: -0.02 (NI 5.99b - CFO 9.43b) / TA 158b) |
| Beneish M = -3.06 (Cap -4..+1) = AA |
As of November 18, 2026, the stock is trading at USD 294.06 with a total of 1,534,215 shares traded. Over the past week, the price has changed by -2.99%, over one month by -1.49%, over three months by +7.40% and over the past year by +10.83%.
Current recommended Stop Loss: 283.10 (which is 3.7% or 1.3 ATR below the current price).
The Cigna has received a consensus analysts rating of 4.21. Therefore, it is recommended to buy CI.
- StrongBuy: 12
- Buy: 5
- Hold: 7
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 345 | 17.3% |
P/E Trailing = 13.0952
P/E Forward = 8.8339
P/S = 0.2733
P/B = 1.7995
P/EG = 0.7485
Revenue TTM = 286b USD
EBIT TTM = 9.64b USD
EBITDA TTM = 12.5b USD
Long Term Debt = 28.8b USD (from longTermDebt, last quarter)
Short Term Debt = 2.29b USD (from shortTermDebt, last quarter)
Debt = 31.2b USD (from shortLongTermDebtTotal, last quarter) + Leases 87.0m
Net Debt = 23.9b USD (calculated: Debt 31.2b - CCE 7.29b)
Enterprise Value = 102b USD (78.3b + Debt 31.2b - CCE 7.29b)
Interest Coverage Ratio = 6.98 (Ebit TTM 9.64b / Interest Expense TTM 1.38b)
EV/FCF = 12.36x (Enterprise Value 102b / FCF TTM 8.27b)
FCF Yield = 8.09% (FCF TTM 8.27b / Enterprise Value 102b)
FCF Margin = 2.89% (FCF TTM 8.27b / Revenue TTM 286b)
Net Margin = 2.09% (Net Income TTM 5.99b / Revenue TTM 286b)
Gross Margin = 10.26% ((Revenue TTM 286b - Cost of Revenue TTM 257b) / Revenue TTM)
Gross Margin QoQ = 3.25% (prev 20.88%)
Tobins Q-Ratio = 0.65 (Enterprise Value 102b / Total Assets 158b)
Interest Expense / Debt = 4.42% (Interest Expense 1.38b / Debt 31.2b)
Taxrate = 19.22% (1.59b / 8.26b)
NOPAT = 7.78b (EBIT 9.64b * (1 - 19.22%))
Current Ratio = 0.84 (Total Current Assets 47.2b / Total Current Liabilities 56.0b)
Debt / Equity = 0.72 (Debt 31.2b / totalStockholderEquity, last quarter 43.4b)
Debt / EBITDA = 1.91 (Net Debt 23.9b / EBITDA 12.5b)
Debt / FCF = 2.90 (Net Debt 23.9b / FCF TTM 8.27b)
Total Stockholder Equity = 42.5b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.80% (Net Income 5.99b / Total Assets 158b)
RoE = 14.10% (Net Income TTM 5.99b / Total Stockholder Equity 42.5b)
RoCE = 13.51% (EBIT 9.64b / Capital Employed (Equity 42.5b + L.T.Debt 28.8b))
RoIC = 8.06% (NOPAT 7.78b / Invested Capital 96.6b)
WACC = 4.39% (E(78.3b)/V(109b) * Re(4.72%) + D(31.2b)/V(109b) * Rd(4.42%) * (1-Tc(0.19)))
Discount Rate = 4.72% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -91.45 | Cagr: -3.24%
[DCF] Terminal Value 76.79% ; FCFF base≈7.93b ; Y1≈8.70b ; Y5≈11.0b
[DCF] Fair Price = 546.6 (EV 168b - Net Debt 23.9b = Equity 144b / Shares 263.5m; r=8.35% [WACC [floored]]; 5y FCF grow 11.15% → 2.50% )
EPS Correlation: 97.78 | EPS CAGR: 8.39% | SUE: 1.04 | # QB: 1
Revenue Correlation: 96.24 | Revenue CAGR: 14.78% | SUE: 0.91 | # QB: 15
EPS current Quarter (2027-03-31): EPS=8.35 | Chg30d=+0.32% | Revisions=+22% | Analysts=15
EPS current Year (2026-12-31): EPS=30.65 | Chg30d=+0.45% | Revisions=+62% | GrowthEPS=+2.7% | GrowthRev=+5.0%
EPS next Year (2027-12-31): EPS=33.26 | Chg30d=-0.66% | Revisions=+40% | GrowthEPS=+8.5% | GrowthRev=+3.6%
[Analyst] Revisions Ratio: +56% (up=11, down=2)